INTRODUCTION
============

The skeletal muscle L-type Ca^2+^ channel (1,4-dihydropyridine receptor \[DHPR\]) serves as the voltage sensor for excitation--contraction (EC) coupling ([@bib61]), activating Ca^2+^ release from the SR via RYR1 in response to depolarization of the plasma membrane. The interaction with RYR1 also increases the magnitude of the L-type Ca^2+^ current produced by DHPR ([@bib36]; [@bib29]; [@bib5]; [@bib6]; [@bib4]; [@bib55]). Neither of these interactions depends on any obvious diffusible messenger (such as entry of external Ca^2+^), which has led to the idea that there is bidirectional conformational coupling between these two proteins ([@bib61]; [@bib24]; [@bib25]; [@bib38]; [@bib29]). Moreover, freeze-fracture replicas of the plasma membrane at sites of junction with the SR reveal a structural correlate of the functional interaction between DHPR and RYR1 ([@bib14]; [@bib58], [@bib59]; [@bib47]; [@bib55]). Specifically, intramembranous particles in the plasma membrane, which appear to represent DHPRs, are arranged into groups of four (tetrads) with spacing that places them in register with the four subunits of every other RYR1. Moreover, the distance between each DHPR within the tetrad (∼19 nm) is decreased (∼2 nm) by application of a high concentration of ryanodine ([@bib41]), which locks RYR1 in an inactivated, nonconducting state ([@bib15]; [@bib68]). Thus, it seems quite certain that protein--protein interactions link DHPR and RYR1.

Two basic strategies have been used in the search to identify the protein--protein interactions that may couple the DHPR and RYR1. One approach has been biochemical analysis of isolated proteins. With this approach, it has been shown that specific regions of the DHPR bind to, or affect the function of, RYR1 and that specific regions of RYR1 bind to DHPR. This approach has revealed that segments of the α~1S~ II--III loop ([@bib32]), α~1S~ III--IV loop ([@bib33]), and the proximal α~1S~ C terminus ([@bib51]) bind to fragments of RYR1 and that segments of RYR1 bind to DHPR subunits ([@bib51]; [@bib17]). An important limitation of such biochemical approaches is that they may reveal interactions between segments of proteins that do not interact within living cells. Moreover, the interactions revealed by these biochemical approaches have often been difficult to reconcile with results obtained by functional analyses of myotubes after expression of cDNAs encoding wild-type or engineered DHPRs or RYRs ([@bib12]). For the functional analysis of the DHPR, the focus has been on the α~1S~ and β~1a~ subunits because bidirectional signaling is little affected by knockout/knockdown of the γ~1~ ([@bib22]; [@bib64]) or α~2~δ-1 ([@bib39], [@bib40]; [@bib26]; [@bib23]; [@bib63]) subunits. Expression of cDNAs in myotubes null for endogenous β~1~ has revealed that the C terminus of β~1a~ is important for EC coupling ([@bib13]; [@bib52],[@bib53], [@bib54]). Likewise, expression of cDNAs in dysgenic (α~1S~ null) myotubes has shown that EC coupling is critically dependent on the α~1S~ II--III loop (see next paragraph) and is also influenced by the α~1S~ III--IV loop ([@bib65]; [@bib10]).

The α~1S~ II--III loop substituted into the corresponding region of the cardiac DHPR α~1C~ subunit confers skeletal-type coupling ([@bib60]; [@bib16]), and, conversely, substitution into an α~1S~ backbone with the II--III loop of α~1C~ (SkLC; [@bib29]) or α~1M~ (SkLM; [@bib67]; [@bib31]) abolishes bidirectional signaling. However, bidirectional signaling is restored when a critical domain of the α~1S~ II--III loop (residues 720--765; [@bib38]) is reintroduced within SkLC or SkLM ([@bib29]; [@bib67]; [@bib31]). Within the critical domain, a central region (α~1S~ residues 737--751) contains the binding site (residues 737--744) for mAb 1A ([@bib30]) and an adjacent cluster of negative charges (residues 744--751). Within this central region, mutation of Ala^739^, Phe^741^, Pro^742^, or Asp^744^ to its corresponding α~1C~ residue reduces both skeletal-type EC coupling and the binding of mAb 1A, and the secondary structure of residues 744--751 also appears to be important for skeletal-type EC coupling ([@bib30],[@bib31]). On the basis of these results, it has been proposed that some portion of α~1S~ residues 737--751 may bind to and activate RYR1 in response to conformational changes of other regions of the DHPR ([@bib31]).

If conformationally driven interactions between regions of the α~1S~ II--III loop and RYR1 are important for bidirectional signaling, it is important to understand how those interactions are coupled to other regions of the DHPR. Previous work ([@bib3]) has shown that skeletal-type EC coupling is preserved after expression of a one-piece α~1S~ construct lacking residues 671--690 (the peptide As-20 region; [@bib19]). Moreover, two-fragment α~1S~ constructs created by deletion of residues 671--690 ([@bib21]) or 671--700 ([@bib2]) also supported robust EC coupling. Although these results indicate that coupling does not require the presence of the peptide A region or the connection of the critical domain to α~1S~ repeat II via the peptide backbone, they do not exclude a modulatory role for this segment of the α~1S~ II--III loop, which has been recently reported to bind in vitro to a fragment of RYR1 (residues 1,085--1,208; [@bib18]; [@bib57]).

It is important to note that the α~1S~ II--III loop region extending from within the C-terminal portion of the critical domain to α~1S~ repeat III has not been adequately tested because this region of the loop is overall considerably conserved between α~1S~ and the corresponding regions of α~1C~ and α~1M~ ([@bib67]). To examine more systematically the importance of different portions of the α~1S~ II--III loop, we introduced perturbations at distinct sites within the loop. In particular, we introduced substantial extra mass (one or two fluorescent proteins) at various sites. The rationale for this approach is that one would expect that sites able to accommodate this insertion without affecting function could neither directly interact with other junctional proteins nor undergo large conformational changes during EC coupling.

We have found that bidirectional coupling is not affected by insertion of a tandem of fluorescent proteins (aggregate mass of ∼56 kD) in place of α~1S~ residues 672--685, adding support to the prevailing view that regions of the α~1S~ II--III loop flanking this insertion site do not undergo important conformational changes and that the critical domain does not interact with more proximal portions of the loop. We found that insertions located more toward the C-terminal end of the loop had a much larger impact on bidirectional signaling. Thus, bidirectional coupling was totally abolished by insertion of the tandem within the critical domain's N-terminal boundary (between α~1S~ residues 726 and 727) but only partially ablated by insertion of a single fluorescent protein at this site. However, bidirectional signaling was essentially ablated by the insertion of a single yellow fluorescent protein (YFP) near the C-terminal boundary of the critical domain (between α~1S~ residues 760 and 761). This also occurred when a single YFP was inserted between α~1S~ residues 785 and 786, which is C terminal to the critical domain and well conserved between α~1S~, α~1C~, and α~1M~. Control experiments indicated that these insertions did not interfere with membrane expression or targeting to peripheral junctions. Thus, our results raise the possibility that the signaling functions of the critical domain depend on its linkage to α~1S~ repeat III via the C-terminal portion of the α~1S~ II--III loop. Alternatively, this conserved region of the α~1S~ II--III loop may be an important site of protein--protein interaction required for signaling.

MATERIALS AND METHODS
=====================

Molecular biology
-----------------

The constructions of YFP-α~1S~, α~1S~(671-CFP-YFP-686), and α~1S~(671-CFP-YFP) + (686)α~1S~ were previously described in [@bib42]. All residue numbers refer to the amino sequence of rabbit α~1S~ (GenBank/EMBL/DDBJ accession no. [X05921](X05921)).

### α~1S~(671-CFP) and (YFP-686)α~1S~.

α~1S~(671-CFP) and (YFP-686)α~1S~ encode, respectively, (a) α~1S~ residues 1--671 followed by an 11-residue linker and by cyan fluorescent protein (CFP) and (b) YFP followed by a 12-residue linker and by α~1S~ residues 686--1,860. To make α~1S~(671-CFP), the sequence encoding α~1S~ 1--671 (2,039 bp) was excised from α~1S~(671-CFP-YFP) with HindIII and KpnI and ligated into the polylinker of the mammalian expression vector pECFP-N1 (Clontech Laboratories, Inc.) cleaved by HindIII and KpnI (4,706-bp fragment). To make (YFP-686)α~1S~, the sequence encompassing the region encoding YFP (769 bp) was excised from pEYFP-C1 (Clontech Laboratories, Inc.), which had been modified to bring the HindIII site into frame for the subsequent cloning procedure. Specifically, an XhoI--SalI fragment of the pEYFP-N1 polylinker encompassing the HindIII site was reversed by ligation into the compatible NheI and HindIII, which are sites of (686)α~1S~ ([@bib42]) opened by NheI and HindIII (7,843 bp).

### α~1S~(671) and (CFP-YFP-686)α~1S~.

α~1S~(671) and (CFP-YFP-686)α~1S~ encode, respectively, (a) α~1S~ residues 1--671 followed by a 12-residue linker and (b) the CFP--YFP tandem (separated by a 23-residue linker) followed by a 12-residue linker and by α~1S~ residues 686--1,860. To make untagged α~1S~(671), the sequence encoding α~1S~(671) (2,039 bp) was removed from α~1S~(671-CFP) (see previous paragraph) with HindIII and KpnI and inserted into the backbone (3,973 bp) of untagged (686)α~1S~, from which the sequence encoding (686)α~1S~ had been excised by digestion with HindIII and KpnI. To make (CFP-YFP-686)α~1S~, the sequence encoding CFP (794 bp) was excised from pECFP-C1 (Clontech Laboratories, Inc.) with NheI and XmaI and ligated into (YFP-686)α~1S~ (see previous paragraph) cleaved with NheI and AgeI (8,243 bp). XmaI and AgeI cleavage sites are compatible for relegation.

### α~1S~(726-CFP-YFP-727).

α~1S~(726-CFP-YFP-727) encodes (in order) (a) α~1S~ residues 1--726, (b) a four-residue linker, (c) CFP--YFP, (d) a 21-residue linker, and (e) α~1S~ residues 727--1,860. CFP-YFP-β~1a~ ([@bib42]) was cut with AgeI and XmaI. A 1,574-bp fragment encoding the CFP--YFP tandem and the aforementioned linkers were subsequently ligated into the untagged α~1S~ expression vector ([@bib42]) in which an AgeI recognition sequence was introduced between the triplets encoding Glu^726^ and Ser^727^ via site-directed PCR mutagenesis (QuikChange; Agilent Technologies).

### α~1S~(726-YFP-727).

α~1S~(726-YFP-727) encodes (in order) (a) α~1S~ residues 1--726, (b) a four-residue linker, (c) YFP, (d) a 21-residue linker, and (e) α~1S~ residues 727--1,860. A 786-bp sequence encoding YFP was excised from pEYFP-C1 using AgeI and XmaI. The resultant fragment was ligated into the untagged α~1S~ expression vector in which an AgeI recognition sequence was introduced between the triplets encoding Glu^726^ and Ser^727^ via site-directed PCR mutagenesis.

### α~1S~(760-YFP-761).

α~1S~(760-YFP-761) encodes (in order) (a) α~1S~ residues 1--760, (b) a single-residue linker, (c) YFP, (d) a three-residue linker, and (d) α~1S~ residues 761--1,860. PCR was used to generate a YFP cDNA with 5′ and 3′ NotI restriction sites from pEYFP-N1. The forward primer was 5′-GCGCGCGGCCGCAAATGGTGAGCAAGGGCG-3′, and the reverse primer was 5′-GCGCGCGCGGCCGCTTCTTGTACAGCTCGTCCATGCC-3′. The resultant PCR product was subcloned into a YFP-α~1S~ ([@bib42]) plasmid that contained a NotI site between the α~1S~ triplets encoding Pro^760^ and Leu^761^ introduced by site-directed mutagenesis with QuikChange primers 5′-GCCCCCGACCGCGGCCGCTGGCCCGAGCTGC-3′ (forward) and 5′-GCAGCTCGGCCAGCGGCCGCGGTCGGGGGC-3′ (reverse). This plasmid was then digested with HindIII and MfeI to excise the segment containing α~1S~(760-YFP-761), from which the sequence encoding the N-terminal YFP had been removed, and was subcloned into pEYFP-N1 cut with HindIII and MfeI.

### α~1S~(785-YFP-786).

α~1S~(785-YFP-786) encodes (in order) (a) α~1S~ residues 1--785, (b) a four-residue linker, (c) YFP, (d) a 22-residue linker, and (e) α~1S~ residues 786--1,860. PCR was used to generate a YFP/linker cDNA with 5′ and 3′ AgeI restriction sites from α~1S~(726-YFP-727). The forward primer was 5′-GCGCGCGACCGGTGTCGCCACCATGGTGAGCAAGG-3′, and the reverse primer was 5′-GCGCGCGACCGGTCGGGCCCGCGGTACCGT-3′. An 812-bp PCR product encoding YFP and the aforementioned linkers was subsequently cut with AgeI and ligated into the untagged α~1S~ expression vector in which a GGT triplet (encoding Gly) had been introduced to form a unique AgeI recognition sequence between the triplets encoding Thr^785^ and Asn^786^. Restriction digests and sequencing were used to verify each cDNA construct.

Expression of cDNA
------------------

All procedures involving mice were approved by the University of Colorado Denver Institutional Animal Care and Use Committee. Primary cultures of phenotypically normal (+/+ or +/*mdg*) or dysgenic (*mdg*/*mdg*) myotubes were prepared from newborn mice as described previously ([@bib11]). For electrophysiological experiments, myoblasts were plated into 35-mm plastic culture dishes (Falcon) coated with entactin--collagen IV--laminin (Millipore). Myoblasts destined for immunocytochemistry were plated into 35-mm culture dishes with entactin--collagen IV--laminin--coated glass coverslip bottoms (MatTek). Cultures were grown for 6--7 d in a humidified 37°C incubator with 5% CO~2~ in Dulbecco's modified Eagle's medium (Mediatech) supplemented with 10% fetal bovine serum/10% horse serum (Hyclone Laboratories). This medium was then replaced with differentiation medium (Dulbecco's modified Eagle's medium supplemented with 2% horse serum). 2--4 d after the shift to differentiation medium, single nuclei were microinjected with cDNA. For one-piece constructs (α~1S~(671-CFP-YFP-686), α~1S~(726-CFP-YFP-727), α~1S~(726-YFP-727), α~1S~(760-YFP-761), or α~1S~(785-YFP-786)), myotubes to be used in electrophysiological experiments were injected with 100 ng/µl cDNA, and myotubes to be immunostained were injected with 60 ng/µl cDNA. For electrophysiology on two-piece constructs, the injection solution contained 60 ng/µl α~1S~(671) hemichannel cDNA and 100 ng/µl (686)α~1S~ hemichannel cDNA. Only myotubes exhibiting YFP fluorescence were used in experiments.

Measurement of ionic currents
-----------------------------

For electrophysiological experiments, myotubes were examined 2 d after injection. Pipettes were fabricated from borosilicate glass and had resistances of ∼2.0 MΩ when filled with internal solution, which consisted of 140 mM Cs-aspartate, 10 mM Cs~2~-EGTA, 5 mM MgCl~2~, and 10 mM HEPES, pH 7.4, with CsOH. The standard external solution contained 145 mM TEA-Cl, 10 mM CaCl~2~, 0.003 mM tetrodotoxin, and 10 mM HEPES, pH 7.4, with TEA-OH. In some experiments, 10 mM MgCl~2~ was substituted for 10 mM CaCl~2~ in the external solution. Linear capacitative and leakage currents were determined by averaging the currents elicited by 11 30-mV hyperpolarizing pulses from a holding potential of −80 mV. Test currents were corrected for linear components of leak and capacitive current by digital scaling and subtraction of this average control current. Electronic compensation was used to reduce the effective series resistance (usually to \<1 MΩ) and the time constant for charging the linear cell capacitance (usually to \<0.5 ms). Ionic currents were filtered at 2 kHz and digitized at 10 kHz. To measure macroscopic L-type current in isolation, a 1-s prepulse to −20 mV followed by a 100-ms repolarization to −50 mV was administered before the test pulse (prepulse protocol; [@bib1]) to inactivate T-type Ca^2+^ channels. Cell capacitance was determined by integration of a transient from −80 to −70 mV using Clampex 8.0 (MDS Analytical Technologies) and was used to normalize current amplitudes (pA/pF). Current--voltage (I-V) curves were fitted using the following equation:$$\text{I} = \text{G}_{\text{max}} \times \left( \text{V} - \text{V}_{\text{rev}}\operatorname{)/\lbrack}1 + \text{exp}\operatorname{\{-(}\text{V} - \text{V}_{1/2}\operatorname{)/}\text{k}_{\text{G}}\operatorname{\}\rbrack} \right.$$where I is the current for the test potential V, V~rev~ is the reversal potential, G~max~ is the maximum Ca^2+^ channel conductance, V~1/2~ is the half-maximal activation potential, and k~G~ is the slope factor. All electrophysiological experiments were performed at room temperature (∼25°C).

Measurement of intracellular Ca^2+^ transients
----------------------------------------------

Changes in intracellular Ca^2+^ were recorded with Fluo-3 (Invitrogen). The salt form of the dye was added to the standard internal solution for a final concentration of 200 µM. After entry into the whole cell configuration, a waiting period of \>5 min was used to allow the dye to diffuse into the cell interior. A 100-W mercury illuminator and a set of fluorescein filters were used to excite the dye present in a small rectangular region of the voltage-clamped myotube. A computer-controlled shutter was used to block illumination in the intervals between test pulses. Fluorescence emission was measured by means of a fluorometer apparatus (Biomedical Instrumentation Group, University of Pennsylvania). The average background fluorescence was quantified before bath immersion of the patch pipette. Fluorescence data are expressed as the total change in fluorescence (ΔF/F), where ΔF represents the change in peak fluorescence from baseline during the test pulse and F is the fluorescence immediately before the test pulse minus the average background (non--Fluo-3) fluorescence. Unless otherwise noted, the peak value of the fluorescence change (ΔF/F) for each test potential (V) was fitted according to$$\text{ΔF}/\text{F} = \left\lbrack \text{ΔF}/\text{F} \right\rbrack_{\text{max}}\operatorname{/\lbrack}1 + \text{exp}\operatorname{\{-(}\text{V} - \text{V}_{\text{F}}\operatorname{)/}\text{k}_{\text{F}}\operatorname{\}\rbrack}$$where (ΔF/F)~max~ is the maximal fluorescence change, V~F~ is the potential causing half the maximal change in fluorescence, and k~F~ is a slope parameter. In the cases of α~1S~(760-YFP-761) and α~1S~(785-YFP-786), the ΔF/F~max~-V relationship was fit by$$\left. \text{ΔF}/\text{F} = \left\lbrack \text{ΔF}/\text{F} \right\rbrack_{\text{max}} \times \text{exp}\operatorname{\{-}0.5\left. \operatorname{((}\text{V} - \text{V}_{\text{c}}\operatorname{)/}\text{b} \right)^{2} \right\}$$where (ΔF/F)~max~ is the maximal fluorescence change and V~c~ and b are fit parameters ([@bib66]).

Measurement of charge movements
-------------------------------

For measurement of intramembrane charge movements, ionic currents were blocked by the addition of 0.5 mM CdCl~2~ + 0.1 mM LaCl~3~ to the standard extracellular recording solution. All charge movements were corrected for linear cell capacitance and leakage currents using a −P/8 subtraction protocol ([@bib9],[@bib10]). Filtering was at 2 kHz (eight-pole Bessel filter; Frequency Devices, Inc.), and digitization was at 20 kHz. Voltage clamp command pulses were exponentially rounded with a time constant of 50--500 µs, and the prepulse protocol ([@bib1]) was used to reduce the contribution of gating currents from voltage-gated Na^+^ channels and T-type Ca^2+^ channels. The integral of the ON transient (Q~on~) for each test potential (V) was fitted according to$$\text{Q}_{\text{on}} = \text{Q}_{\text{max}}\operatorname{/\{}1 + \text{exp}\operatorname{\lbrack-(}\text{V} - \text{V}_{\text{Q}}\operatorname{)/}\text{k}_{\text{Q}}\operatorname{\rbrack\}}$$where Q~max~ is the maximal Q~on~, V~Q~ is the potential causing movement of half the maximal charge, and k~Q~ is a slope parameter.

Electrically evoked contractions
--------------------------------

Contractions were elicited by 20-ms, 100-V stimuli applied via an extracellular pipette that contained 150 mM NaCl and was placed near intact myotubes expressing constructs of interest. The myotubes were bathed in Rodent Ringer's solution (146 mM NaCl, 5 mM KCl, 2 mM CaCl~2~, 1 mM MgCl~2~, 10 mM HEPES, and 11 mM glucose, pH 7.4, with NaOH). Contractions were assayed by the movement of an identifiable portion of a myotube across the visual field.

Immunohistochemistry
--------------------

2 d after the injection, myotubes were washed twice in Ca^2+^/Mg^2+^-free Ringer's solution (146 mM NaCl, 5 mM KCl, 10 mM HEPES, and 11 mM glucose, pH 7.4, with NaOH) and fixed in 4% paraformaldehyde solution in PBS (Sigma-Aldrich) for 20 min. Myotubes were then permeabilized with 0.1% Triton X-100/PBS for 30 min. After another PBS wash, nonspecific reactivity was blocked by application of 1% BSA/PBS for 2 h. The primary antibody (mouse anti-α~1S~, 1:2,000; Thermo Fisher Scientific; also referred to as mAb 1A) was applied overnight at room temperature (∼25°C) in a dark, humid environment. The next day, myotubes were again washed with 1% BSA/PBS. The secondary antibody (Alexa Fluor 568--conjugated goat anti--mouse IgG, 1:4,000; Invitrogen) was applied in the dark for 1 h at room temperature. Excess secondary antibody was removed with three 1% BSA/PBS washes. Finally, immunostained myotubes were rinsed with PBS.

Confocal microscopy
-------------------

Immunostained myotubes were examined in PBS using a confocal laser-scanning microscope (LSM 510 META; Carl Zeiss, Inc.). An area of 500--2,500 µm^2^ was selected from the field of view (63× 1.4 NA oil immersion objective), which included the myotube and also an adjacent noncellular region for measurement of background fluorescence. YFP was excited with the 488-nm line of an argon laser (30-mW maximum output, operated at 50% or 6.3 A), and Alexa Fluor 568 was excited with a separate sweep of the 543-nm line from a HeNe laser (1-mW maximum output, operated at 100%), which were directed to the cell via a 488/543-nm dual dichroic mirror. The emitted YFP fluorescence was directed to a photomultiplier equipped with a 505--530 band-pass filter (Chroma Technology Corp.). For Alexa Fluor 568, the emitted fluorescence was directed to a photomultiplier equipped with a 560-nm long-pass filter. Confocal fluorescence intensity data were recorded as the average of four line scans per pixel and digitized at 8 bits, with photomultiplier gain adjusted such that maximum pixel intensities were no more than ∼70% saturated.

Analysis
--------

For calculation of G~max~/Q′ ratios, G~max~ was obtained by [Eq. 1](#fd1){ref-type="disp-formula"}, whereas Q′ was derived by subtracting the average maximal charge movement of dysgenic myotubes (Q~dys~) from the average total Q~max~, where Q~dys~ = 1.0 nC/μF (*n* = 6; [Table I](#tbl1){ref-type="table"}). Figures were made using the software program SigmaPlot (version 7.0 or 11.0; SSPS Inc.). All data are presented as mean ± SEM. Statistical comparisons were made by ANOVA or by unpaired, two-tailed *t* test (as appropriate), with P \< 0.05 considered significant.

###### 

α~1S~ fluorescent protein construct conductance and intramembrane charge movement

  Construct                                    *G-V*                                            *Q-V*                                         G~max~/Q′                                                                                                                 
  -------------------------------------------- ------------------------------------------------ --------------------------------------------- --------------------------------------------- --------------- ---------------------------------------------- ------------ ---------
                                               *nS/nF*                                          *mV*                                          *mV*                                          *nC/μF*         *mV*                                           *mV*         *nS/pC*
  α~1S~-YFP[a](#tblfn1){ref-type="table-fn"}   140 ± 5 (37)                                     31.2 ± 0.8                                    8.1 ± 0.2                                     6.0 ± 0.4 (8)   −3.2 ± 2.0                                     9.0 ± 0.7    33
  α~1S~(671-CFP-YFP) + (686)α~1S~              174 ± 13 (20)                                    36.0 ± 0.9                                    7.4 ± 0.3                                     4.2 ± 0.8 (7)   −9.5 ± 4.5                                     9.2 ± 0.6    54
  α~1S~(671) + (CFP-YFP-686)α~1S~              144 ± 13 (20)                                    35.5 ± 1.1                                    7.8 ± 0.3                                     3.5 ± 1.4 (4)   −11.1 ± 6.6                                    9.3 ± 1.4    58
  α~1S~(671-CFP) + (YFP-686)α~1S~              164 ± 15 (18)                                    36.0 ± 1.1                                    7.4 ± 0.4                                     4.4 ± 1.1 (5)   −4.8 ± 5.4                                     5.3 ± 2.6    48
  α~1S~(671-CFP-YFP-686)                       182 ± 11 (33)                                    33.9 ± 1.1                                    7.3 ± 0.3                                     6.3 ± 0.8 (7)   −3.1 ± 0.8                                     11.3 ± 0.7   34
  α~1S~(726-CFP-YFP-727)                       67 ± 5 (30)[b](#tblfn2){ref-type="table-fn"}     38.5 ± 1.8[d](#tblfn4){ref-type="table-fn"}   10.4 ± 0.7[b](#tblfn2){ref-type="table-fn"}   5.4 ± 0.9 (6)   −12.2 ± 4.1[d](#tblfn4){ref-type="table-fn"}   11.7 ± 1.4   15
  α~1S~(726-YFP-727)                           116 ± 11 (15)[b](#tblfn2){ref-type="table-fn"}   35.1 ± 2.2                                    9.7 ± 0.7[b](#tblfn2){ref-type="table-fn"}    6.9 ± 0.6 (6)   −12.1 ± 1.4[b](#tblfn2){ref-type="table-fn"}   13.4 ± 0.9   20
  α~1S~(760-YFP-761)                           102 ± 10 (12)[b](#tblfn2){ref-type="table-fn"}   34.1 ± 0.9                                    9.2 ± 0.7[c](#tblfn3){ref-type="table-fn"}    8.0 ± 1.6 (5)   −7.6 ± 1.8[c](#tblfn3){ref-type="table-fn"}    14.0 ± 1.4   15
  α~1S~(785-YFP-786)                           72 ± 10 (12)[b](#tblfn2){ref-type="table-fn"}    38.9 ± 3.4                                    9.5 ± 1.7                                     5.2 ± 0.8 (5)   −11.3 ± 4.8                                    12.5 ± 1.0   17
  Uninjected dysgenic myotubes                 no inward current (17)                           no inward current (17)                        no inward current (17)                        1.0 ± 0.2 (6)   −5.0 ± 4.6                                     9.6 ± 3.0    ND

Data are given as mean ± SEM, with the numbers in parentheses indicating the number of myotubes tested. See Materials and methods for fits. For all of the data given, the calculated average voltage error was \<5 mV. Significant differences between α~1S~(671-CFP-YFP-686) and the other individual one-piece constructs (i.e., α~1S~(726-CFP-YFP-727), α~1S~(726-YFP-727), α~1S~(760-YFP-761), and α~1S~(785-YFP-786)) are indicated.

α~1S~-YFP data from [@bib8] are included for comparison.

P \< 0.001 by *t* test.

P \< 0.01 by *t* test.

P \< 0.05 by *t* test.

Online supplemental material
----------------------------

Fig. S1 confirms that α~1S~(726-YFP-727) partially supports skeletal-type EC coupling. Myoplasmic Ca^2+^ transients and L-type currents were recorded with 10 mM Mn^2+^ substituted for 10 mM Ca^2+^ in the bath solution. Online supplemental material is available at <http://www.jgp.org/cgi/content/full/jgp.200910241/DC1>.

RESULTS
=======

The overall aim of this study was to determine how perturbing the DHPR α~1S~ II--III loop with inserted fluorescent proteins affects bidirectional interactions with RYR1. These constructs are illustrated in [Fig. 1](#fig1){ref-type="fig"} and represent insertions into the peptide A region ([Fig. 1, A--D](#fig1){ref-type="fig"}), into the N-terminal portion of the critical domain ([Fig. 1, E and F](#fig1){ref-type="fig"}), near the C-terminal edge of the critical domain ([Fig. 1 G](#fig1){ref-type="fig"}), and the conserved segment of the α~1S~ II--III loop that intervenes between the critical domain and repeat III ([Fig. 1 H](#fig1){ref-type="fig"}).

![Schematic diagrams of the fluorescent protein α~1S~ fusion constructs. The red segment of the α~1S~ II--III loop represents the EC coupling critical domain (α~1S~ residues 720--765; [@bib38]). The linker sequences (see Materials and methods) connecting CFP and YFP to one another and linking the fluorescent proteins to α~1S~ are indicated by wavy lines. (A--D) α~1S~ constructs in which a CFP--YFP tandem was substituted for α~1S~ residues 672--685 (i.e., the tandem replaced the peptide A region). (E and F) α~1S~ constructs in which either the CFP--YFP tandem (E) or a single YFP (F) was introduced between α~1S~ residues 726 and 727. This position lies just inside the N-terminal portion of the critical domain. (G) α~1S~ construct in which YFP was inserted in between residues 760 and 761. This position lies just inside the C-terminal edge of the critical domain. (H) α~1S~ construct in which YFP was inserted between residues 785 and 786. This position lies in the highly conserved C-terminal region of the α~1S~ II--III loop between the critical domain and α~1S~ repeat III.](JGP_200910241_RGB_Fig1){#fig1}

Insertions into the peptide A region
------------------------------------

Previous work monitored the fluorescence resonance energy transfer efficiency of an ∼56-kD CFP--YFP tandem inserted in place of the peptide A region of the α~1S~ II--III loop (residues 671--686) as an indicator of spatial environment ([@bib42]). The fluorescence resonance energy transfer efficiency showed a small dependence on whether or not RYR1 was present when CFP--YFP replaced α~1S~ residues 672--685 in a one-piece construct ([Fig. 1 A](#fig1){ref-type="fig"}) but no dependence when the tandem was fused to the C terminus of an α~1S~ I--II hemichannel (after α~1S~ residue 671) and was coexpressed with an α~1S~ III--IV hemichannel (beginning at α~1S~ residue 686; [Fig. 1 B](#fig1){ref-type="fig"}). Thus, in this study, we examined these two constructs in more detail as well as two additional constructs centered on this location. In α~1S~(671) + (CFP-YFP-686)α~1S~, the division was made before the tandem ([Fig. 1 C](#fig1){ref-type="fig"}), and in α~1S~(671-CFP) + (YFP-686)α~1S~, the tandem was split, and the fluorescent proteins resided separately on each hemidomain ([Fig. 1 D](#fig1){ref-type="fig"}).

L-type Ca^2+^ currents for the four sets of constructs after expression in dysgenic myotubes are shown in [Fig. 2](#fig2){ref-type="fig"}. The one-piece construct α~1S~(671-CFP-YFP-686) produced large-amplitude L-type Ca^2+^ currents (−6.6 ± 0.5 pA/pF at 50 mV; *n* = 33) with an I-V relationship (V~1/2~ = 33.9 ± 1.1 mV; [Fig. 2 A](#fig2){ref-type="fig"}) that were similar to those reported previously for other fluorescent protein--tagged DHPRs ([Table I](#tbl1){ref-type="table"}; [@bib28]; [@bib67], [@bib21]; [@bib42]; [@bib8]; [@bib10]). The construct pairs α~1S~(671-CFP-YFP) + (686)α~1S~ and α~1S~(671-CFP) + (YFP-686)α~1S~ produced currents similar to those of α~1S~(671-CFP-YFP-686) in both magnitude (−6.2 ± 0.6 pA/pF \[*n* = 20\] and −5.8 ± 0.8 pA/pF \[*n* = 18\], respectively; P \> 0.05, ANOVA) and voltage dependence (P \> 0.05, ANOVA; [Table I](#tbl1){ref-type="table"}). The construct pair α~1S~(671) + (CFP-YFP-686)α~1S~ produced currents with a peak current density (−4.5 ± 0.5 pA/pF at 50 mV; *n* = 20) slightly lower relative to the other two hemichannel combinations (P \> 0.05, ANOVA; [Fig. 2 C](#fig2){ref-type="fig"}), despite having similar membrane expression (as assessed by intramembrane charge movement; P \> 0.05, ANOVA; [Table I](#tbl1){ref-type="table"}). However, it is possible that some of the charge movement for the two-piece constructs was produced by α~1S~ I--II hemidomains unpartnered with α~1S~ III--IV hemidomains ([@bib2]; [@bib21]). Dysgenic myotubes expressing each of the four sets of constructs with the CFP--YFP tandem introduced in place of the peptide A region produced contractions in response to extracellular electrical stimuli ([Table II](#tbl2){ref-type="table"}).

![L-type currents are little affected by replacement of α~1S~ residues 672--685 with a CFP--YFP tandem. Peak I-V relationships are shown for dysgenic myotubes expressing α~1S~(671-CFP-YFP-686) (A), α~1S~(671-CFP-YFP) + (686)α~1S~ (B), α~1S~(671) + (CFP-YFP-686)α~1S~ (C), and α~1S~(671-CFP) + (YFP-686)α~1S~ (D). Currents were evoked at 0.1 Hz by 200-ms test potentials ranging from −20 through 80 mV in 10-mV increments after a prepulse protocol ([@bib1]). Current amplitudes were normalized by linear cell capacitance (pA/pF). Representative current families (test potentials of −20, 0, 20, and 40 mV) for each construct are shown in the insets. Vertical scale bar, 5 pA/pF; horizontal scale bar, 50 ms. The smooth I-V curves are plotted according to [Eq. 1](#fd1){ref-type="disp-formula"}, with the best fit parameters for each plot presented in [Table I](#tbl1){ref-type="table"}. Error bars represent ±SEM.](JGP_200910241_LW_Fig2){#fig2}

Depolarization-triggered myoplasmic Ca^2+^ transients for these constructs are shown in [Fig. 3](#fig3){ref-type="fig"}. α~1S~(671-CFP-YFP-686) triggered robust Ca^2+^ transients (\[ΔF/F\]~max~ = 0.69 ± 0.12; *n* = 7) with an amplitude that had a sigmoidal dependence on test potential ([Table II](#tbl2){ref-type="table"} and [Fig. 3 A](#fig3){ref-type="fig"}), a signature characteristic of skeletal-type EC coupling ([@bib24]; [@bib25]). Likewise, α~1S~(671-CFP-YFP) + (686)α~1S~ (\[ΔF/F\]~max~ = 0.61 ± 0.08; *n* = 9) and α~1S~(671-CFP) + (YFP-686)α~1S~ (\[ΔF/F\]~max~ = 0.93 ± 0.14; *n* = 7) also served as effective voltage sensors for EC coupling ([Table II](#tbl2){ref-type="table"} and [Fig. 3, B and D](#fig3){ref-type="fig"}). α~1S~(671) + (CFP-YFP-686)α~1S~ had a slightly reduced ability to trigger myoplasmic Ca^2+^ release (\[ΔF/F\]~max~ = 0.48 ± 0.07; *n* = 6; P \< 0.05, ANOVA; [Fig. 3 C](#fig3){ref-type="fig"} and [Table II](#tbl2){ref-type="table"}). This slight reduction in ability to mediate EC coupling mirrored the reduced L-type current produced by α~1S~(671) + (CFP-YFP-686)α~1S~ ([Fig. 2 C](#fig2){ref-type="fig"}). However, the main conclusion that can be drawn from the experiments illustrated in [Figs. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} is that introduction of the CFP--YFP tandem in place of α~1S~ residues 672--685 had little or no effect on the ability of DHPR to conduct L-type Ca^2+^ current or to support EC coupling.

![EC coupling is little affected by replacement of α~1S~ residues 672--685 with a CFP--YFP tandem. ΔF/F-V relationships are shown for dysgenic myotubes expressing α~1S~(671-CFP-YFP-686) (A), α~1S~(671-CFP-YFP) + (686)α~1S~ (B), α~1S~(671) + (CFP-YFP-686)α~1S~ (C), and α~1S~(671-CFP) + (YFP-686)α~1S~ (D). Transients were elicited at 0.1 Hz by 200-ms test potentials ranging from −20 through 80 mV in 10-mV increments after a prepulse protocol ([@bib1]). The smooth ΔF/F-V curves are plotted according to [Eq. 2](#fd2){ref-type="disp-formula"}, with the best fit parameters for each plot presented in [Table II](#tbl2){ref-type="table"}. Representative transient families (test potentials of −20, 0, 20, 40, and 60 mV) are shown for each construct in the insets. Vertical scale bar, 0.5 ΔF/F; horizontal scale bar, 25 ms. Error bars represent ±SEM.](JGP_200910241_LW_Fig3){#fig3}

###### 

Ability of fluorescent protein-tagged DHPRs to restore EC coupling

  Construct                                    ΔF/F-V                                             Contracting cells/number tested                                                             
  -------------------------------------------- -------------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------
                                                                                                  *mV*                                          *mV*                                          
  α~1S~-YFP[a](#tblfn5){ref-type="table-fn"}   0.58 ± 0.09 (15)                                   6.6 ± 1.6                                     4.7 ± 0.4                                     41/47
  α~1S~(671-CFP-YFP) + (686)α~1S~              0.61 ± 0.08 (9)                                    0.4 ± 1.5                                     3.7 ± 0.4                                     9/11[b](#tblfn6){ref-type="table-fn"}
  α~1S~(671) + (CFP-YFP-686)α~1S~              0.48 ± 0.07 (6)                                    7.1 ± 2.0                                     3.7 ± 0.4                                     12/15
  α~1S~(671-CFP) + (YFP-686)α~1S~              0.93 ± 0.14 (7)                                    7.8 ± 1.5                                     4.1 ± 0.4                                     10/25
  α~1S~(671-CFP-YFP-686)                       0.69 ± 0.12 (7)                                    −0.3 ± 2.7                                    4.9 ± 1.1                                     26/32
  α~1S~(726-CFP-YFP-727)                       No fit (12)                                        No fit                                        No fit                                        0/52
  α~1S~(726-YFP-727)                           0.19 ± 0.08 (7)[c](#tblfn7){ref-type="table-fn"}   11.9 ± 3.2[d](#tblfn8){ref-type="table-fn"}   10.0 ± 2.8[d](#tblfn8){ref-type="table-fn"}   5/56
  α~1S~(726-YFP-727) (10 mM Mg^2+^ external)   0.29 ± 0.17 (4)                                    4.4 ± 6.0                                     9.1 ± 2.0                                     ND
  α~1S~(760-YFP-761)                           See legend (6)                                     See legend                                    See legend                                    0/72
  α~1S~(785-YFP-786)                           No fit (3)                                         No fit                                        No fit                                        0/29
  Uninjected dysgenic myotubes                 No fit (8)                                         No fit                                        No fit                                        0/100

Data are given as mean ± SEM, with the numbers in parentheses indicating the number of myotubes tested. All ΔF/F-V data given were fit with [Eq. 2](#fd2){ref-type="disp-formula"} except for α~1S~(760-YFP-761). The ΔF/F-V relationship for α~1S~(760-YFP-761) was best fit by the Gaussian function ΔF/F = \[ΔF/F\]~max~ × exp{−0.5(V − V~o~/b)^2^}, where \[ΔF/F\]~max~ = 0.1, V~c~ = 49.2 mV, and b = 25.7 mV ([Eq. 3](#fd3){ref-type="disp-formula"}). "No fit" indicates that the ΔF/F-V relationship could not be well fit by either [Eq. 2](#fd2){ref-type="disp-formula"} or [Eq. 3](#fd3){ref-type="disp-formula"} for the number of myotubes indicated. Significant differences between α~1S~(671-CFP-YFP-686) and the other individual one-piece constructs that were fit by [Eq. 2](#fd2){ref-type="disp-formula"} (i.e., α~1S~(726-YFP-727)) are indicated.

α~1S~-YFP data from [@bib8] are included for comparison.

α~1S~(671-CFP-YFP) + (686)α~1S~ contraction data were obtained from [@bib42].

P \< 0.005 by *t* test.

P \< 0.05 by *t* test.

α~1S~ II--III loop insertions distal to the peptide A region
------------------------------------------------------------

We next probed the effects of insertions at more C-terminal sites of the loop ([Fig. 1, E-H](#fig1){ref-type="fig"}). One obvious concern was that these perturbations of the II--III loop might impair expression of the constructs. Thus, we used measurements of membrane-bound charge movements as an indication of membrane expression. These measurements showed that the constructs α~1S~(726-CFP-YFP-727), α~1S~(726-YFP-727), α~1S~(760-YFP-761), and α~1S~(785-YFP-786) all produced charge movements similar in magnitude to those of α~1S~(671-CFP-YFP-686) (P \< 0.05, ANOVA; [Table I](#tbl1){ref-type="table"} and [Fig. 4, A--E](#fig4){ref-type="fig"}), which was able to mediate robust EC coupling and L-type Ca^2+^ current.

![Introduction of fluorescent proteins within either the critical domain or the conserved C-terminal region of the α~1S~ II--III loop does not greatly perturb DHPR membrane expression. Q-V relationships are shown for dysgenic myotubes expressing α~1S~(671-CFP-YFP-686) (A), α~1S~(726-CFP-YFP-727) (B), α~1S~(726-YFP-727) (C), α~1S~(760-YFP-761) (D), and α~1S~(785-YFP-786) (E). Charge movements were measured with 20-ms depolarizations from −50 mV in the presence of Cd^2+^ and La^3+^. Q-V relationships were fit by [Eq. 4](#fd4){ref-type="disp-formula"}; the best fit parameters for each plot are presented in [Table I](#tbl1){ref-type="table"}. Error bars represent ±SEM.](JGP_200910241_LW_Fig4){#fig4}

Consequences of fluorescent protein insertion between α~1S~ residues 726 and 727
--------------------------------------------------------------------------------

Based on chimeras of α~1S~ and α~1C~ ([@bib38]), residues 720--765 were found to constitute a critical domain for skeletal-type EC coupling, although it is important to note that such chimeric constructs do not allow one to deduce precise boundaries. Indeed, subsequent work with chimeras of α~1S~ and the *Musca domestica* (common house fly) muscle homologue α~1M~ ([@bib31]) indicated that skeletal-type EC coupling could be produced by constructs in which α~1S~ residues 720--733 were replaced by nonconserved sequence from α~1M~. Thus, we sought to determine whether bidirectional signaling would be affected by larger structural perturbations within this region. In contrast to insertion in the peptide A region, insertion of the CFP--YFP tandem between α~1S~ II--III loop residues 726 and 727, α~1S~(726-CFP-YFP-727), essentially eliminated bidirectional interactions with RYR1 ([Fig. 5 A](#fig5){ref-type="fig"}). Thus, α~1S~(726-CFP-YFP-727) produced currents that were much smaller than those of α~1S~(671-CFP-YFP-686) ([Fig. 5 B](#fig5){ref-type="fig"} and [Table I](#tbl1){ref-type="table"}) despite producing similar intramembrane charge movements ([Fig. 4, A and B](#fig4){ref-type="fig"}; and [Table I](#tbl1){ref-type="table"}). Furthermore, α~1S~(726-CFP-YFP-727) triggered only barely detectable Ca^2+^ transients in the 12 myotubes examined ([Fig. 5 C](#fig5){ref-type="fig"}). Likewise, neither spontaneous nor evoked contractions were observed in dysgenic myotubes expressing α~1S~(726-CFP-YFP-727) (*n* = 52; [Table II](#tbl2){ref-type="table"}).

![Effect on bidirectional signaling of fluorescent protein insertion between α~1S~ residues 726 and 727. (A and D) Simultaneous recordings of myoplasmic Ca^2+^ transients (top) and L-type Ca^2+^ currents (bottom) elicited by 200-ms depolarizations to the indicated test potentials are shown for dysgenic myotubes expressing either α~1S~(726-CFP-YFP-727) (A) or α~1S~(726-YFP-727) (D). (B and E) I-V relationships are shown for α~1S~(726-CFP-YFP-727) and α~1S~(726-YFP-727) in B and E, respectively. The gray lines represent the average I-V relationship for α~1S~(671-CFP-YFP-686). (C and F) ΔF/F-V relationships for α~1S~(726-CFP-YFP-727) and α~1S~(726-YFP-727) are shown in C and F, respectively. The gray lines represent the average ΔF/F-V relationship for α~1S~(671-CFP-YFP-686). The best fit parameters for the data in each panel are presented in [Tables I](#tbl1){ref-type="table"} and [II](#tbl2){ref-type="table"}. Error bars represent ±SEM.](JGP_200910241_GS_Fig5){#fig5}

To determine the effects of introducing a smaller mass at this site, we constructed and characterized an α~1S~ in which a single YFP (∼27 kD) was inserted after residue 726 (α~1S~(726-YFP-727)). In contrast to α~1S~(726-CFP-YFP-727), partial bidirectional signaling occurred for α~1S~(726-YFP-727) ([Fig. 5 D](#fig5){ref-type="fig"}), although this signaling was compromised compared with α~1S~(671-CFP-YFP-686). Thus, L-type current density was more than twofold larger than for α~1S~(726-CFP-YFP-727), although not as large as for α~1S~(671-CFP-YFP-686) ([Fig. 5 E](#fig5){ref-type="fig"} and [Table I](#tbl1){ref-type="table"}). Moreover, α~1S~(726-YFP-727) supported modest myoplasmic Ca^2+^ transients (\[ΔF/F\]~max~ = 0.19 ± 0.08; *n* = 7; [Fig. 5 F](#fig5){ref-type="fig"} and [Table II](#tbl2){ref-type="table"}), which displayed a sigmoidal voltage dependence that was positively shifted (10--20 mV) relative to α~1S~(671-CFP-YFP-686). A small number of evoked contractions were observed in dysgenic myotubes expressing α~1S~(726-YFP-727) (5 of 56 myotubes tested; [Table II](#tbl2){ref-type="table"}).

Although the sigmoidal voltage dependence of the Ca^2+^ transients ([Fig. 5 F](#fig5){ref-type="fig"}) suggested that the modest Ca^2+^ release observed for α~1S~(726-YFP-727) was skeletal type, we further tested the nature of this release by equimolar substitution of Mg^2+^ for Ca^2+^ in the external solution. Substitution of Mg^2+^ for Ca^2+^ had little effect on either the magnitude (\[ΔF/F\]~max~ = 0.29 ± 0.17; *n* = 4; P \> 0.05, *t* test) or the sigmoidal voltage dependence of SR Ca^2+^ release ([Fig. S1](http://www.jgp.org/cgi/content/full/jgp.200910241/DC1)). These results indicate that bidirectional coupling was partially restored by α~1S~(726-YFP-727), although both orthograde and retrograde coupling were impaired.

Bidirectional coupling with RYR1 is disrupted in α~1S~(760-YFP-761)
-------------------------------------------------------------------

With the knowledge that the triad junction can accommodate insertion of a single YFP near the N-terminal boundary of the critical domain, we next tested whether introduction of YFP near the C-terminal boundary of this region, α~1S~(760-YFP-761), would also partially spare bidirectional signaling. This construct produced small Ca^2+^ currents and transients ([Fig. 6 A](#fig6){ref-type="fig"}). On average, α~1S~(760-YFP-761) produced Ca^2+^ currents that were about half the magnitude of those for α~1S~(671-CFP-YFP-686) ([Fig. 6 B](#fig6){ref-type="fig"}). However, α~1S~(760-YFP-761) produced somewhat larger charge movements than the other clones examined ([Fig. 4](#fig4){ref-type="fig"} and [Table I](#tbl1){ref-type="table"}). If this increased membrane expression is taken into account, the magnitude of the currents produced by α~1S~(760-YFP-761) differed little from those of α~1S~(726-CFP-YFP-727) ([Fig. 5 B](#fig5){ref-type="fig"}), as indicated by their equivalent G~max~/Q′ ratios ([Table I](#tbl1){ref-type="table"}).

![Bidirectional signaling is disrupted by insertion of YFP between α~1S~ residues 760 and 761. (A) Simultaneous recordings of myoplasmic Ca^2+^ transients (top) and L-type Ca^2+^ currents (bottom) elicited by 200-ms depolarizations to the indicated test potentials are shown for a dysgenic myotube expressing α~1S~(760-YFP-761). Note the large charge movement relative to small L-type currents and Ca^2+^ transients. (B) I-V relationship for α~1S~(760-YFP-761). The gray line represents the average I-V relationship for α~1S~(671-CFP-YFP-686). (C) Voltage dependence of Ca^2+^ transients from dysgenic myotubes expressing α~1S~(760-YFP-761). The smooth curve for the α~1S~(760-YFP-761) data represents ΔF/F = \[ΔF/F\]~max~ × exp{−0.5(V − V~o~/b)^2^}, where \[ΔF/F\]~max~ = 0.1, V~c~ = 49.2 mV, and b = 25.7 mV ([Eq. 3](#fd3){ref-type="disp-formula"}). The gray line represents the ΔF/F-V relationship for α~1S~(671-CFP-YFP-686). Myoplasmic Ca^2+^ transients were recorded only from myotubes that had quantifiable L-type current. Error bars represent ±SEM.](JGP_200910241_GS_Fig6){#fig6}

Depolarization-elicited Ca^2+^ transients were detectable in dysgenic myotubes expressing α~1S~(760-YFP-761) (\[ΔF/F\]~max~ = 0.10 ± 0.02; *n* = 6; [Fig. 6 A](#fig6){ref-type="fig"}). However, these small transients appeared to be a consequence of Ca^2+^ entry via the L-type current because the ΔF/F-V relationship ([Fig. 6 C](#fig6){ref-type="fig"}) did not display the sigmoidal shape expected for skeletal-type EC coupling but instead mirrored the peak I-V relationship ([Fig. 6 B](#fig6){ref-type="fig"}). No spontaneous or evoked contractions were observed in dysgenic myotubes expressing α~1S~(760-YFP-761) (*n* = 72; [Table II](#tbl2){ref-type="table"}). Thus, it appears that both orthograde and retrograde signaling are largely ablated by insertion of YFP between α~1S~ II--III loop residues 760 and 761.

Bidirectional coupling with RYR1 is also disrupted in α~1S~(785-YFP-786)
------------------------------------------------------------------------

An important limitation of the analysis of chimeras of α~1C~ or α~1M~ with α~1S~ is that the region corresponding to α~1S~ residues 773--799 is quite well conserved between the three α~1~ subunits ([@bib67]). Thus, the chimeras are not informative about the potential importance of this region. Therefore, we directly probed this region by inserting YFP between α~1S~ residues 785 and 786 (α~1S~(785-YFP-786)). Dysgenic myotubes expressing α~1S~(785-YFP-786) produced minimal Ca^2+^ currents and transients ([Fig. 7 A](#fig7){ref-type="fig"}). Thus, current density for α~1S~(785-YFP-786) was very low (−1.4 ± 0.4 pA/pF at 40 mV; *n* = 12; [Fig. 7 B](#fig7){ref-type="fig"}), although it produced charge movements (Q~max~ = 5.2 ± 0.8 nC/μF; *n* = 5; [Fig. 4 E](#fig4){ref-type="fig"}) that were similar to those of the other one-piece constructs that supported bidirectional signaling ([Fig. 4, A and C](#fig4){ref-type="fig"}; and [Table I](#tbl1){ref-type="table"}). The G~max~/Q′ ratio for α~1S~(785-YFP-786) was similar to that of α~1S~(726-CFP-YFP-727) and α~1S~(760-YFP-761) ([Table I](#tbl1){ref-type="table"}).

![Bidirectional signaling is disrupted by insertion of YFP between α~1S~ residues 785 and 786. (A) Simultaneous recordings of myoplasmic Ca^2+^ transients (top) and L-type Ca^2+^ currents (bottom) elicited by 200-ms depolarizations to the indicated test potentials are shown for a dysgenic myotube expressing α~1S~(785-YFP-786). (B) I-V relationship for α~1S~(785-YFP-786). The gray line represents the average I-V relationship for α~1S~(671-CFP-YFP-686). (C) Lack of Ca^2+^ transients in dysgenic myotubes expressing α~1S~(785-YFP-786). The gray line represents the average ΔF/F-V relationship for α~1S~(671-CFP-YFP-686). Myoplasmic Ca^2+^ transients were recorded only from myotubes that had quantifiable L-type current. Error bars represent ±SEM.](JGP_200910241_GS_Fig7){#fig7}

In addition to eliminating retrograde coupling, insertion of YFP between α~1S~ residues 785 and 786 also abolished orthograde coupling, as Ca^2+^ transients were nearly undetectable ([Fig. 7 C](#fig7){ref-type="fig"}). No spontaneous or evoked contractions were observed in dysgenic myotubes expressing α~1S~(785-YFP-786) (*n* = 29; [Table II](#tbl2){ref-type="table"}). These results indicate that insertion of a single fluorescent protein between α~1S~ residues 785 and 786 disrupts bidirectional coupling.

Insertion of fluorescent proteins does not impede antibody binding to the critical domain
-----------------------------------------------------------------------------------------

Within the critical domain, α~1S~ residues 737--744 are recognized by mAb 1A, and mutations within this region were shown to have parallel effects on the immunohistochemical binding of the antibody and on orthograde coupling ([@bib30]). On the basis of this result, it was hypothesized that the appropriate conformation of α~1S~ residues 737--744 is essential for communication between DHPR and RYR1. Thus, we used the strategy illustrated in [Fig. 8 A](#fig8){ref-type="fig"} to test whether mAb 1A could recognize its epitope in the constructs with impaired bidirectional coupling (i.e., α~1S~(726-CFP-YFP-727), α~1S~(726-YFP-727), α~1S~(760-YFP-761), and α~1S~(785-YFP-786); [Figs. 5--7](#fig5){ref-type="fig"}[](#fig6){ref-type="fig"}[](#fig7){ref-type="fig"}). [Fig. 8 B](#fig8){ref-type="fig"} shows for YFP-α~1S~ that the yellow fluorescence (middle, green) and mAb 1A staining (top, red) colocalize in discrete puncta (bottom, yellow). Similarly colocalized puncta of yellow fluorescence and mAb 1A staining were also observed for α~1S~(726-CFP-YFP-727), α~1S~(726-YFP-727), α~1S~(760-YFP-761), and α~1S~(785-YFP-786) ([Fig. 8, C--F](#fig8){ref-type="fig"}). Such puncta were completely absent in dysgenic myotubes not injected with α~1S~ cDNAs (unpublished data). Furthermore, in control experiments in which the primary antibody was omitted, red puncta were absent despite the persistence of puncta generated by YFP fluorescence (unpublished data). Previous work has demonstrated that DHPR puncta in myotubes colocalize with RYR1 ([@bib59]). Thus, the data in [Fig. 8](#fig8){ref-type="fig"} support the idea that each of the fluorescent protein α~1S~ constructs was efficiently targeted to plasma membrane junctions with the SR. In addition, these data demonstrate that the introduction of either a single YFP or a CFP--YFP tandem did not severely disrupt the conformation of the antibody epitope within the critical domain.

![Insertion of fluorescent protein at residues 726, 760, or 785 within the α~1S~ II--III loop does not interfere with recognition of the critical domain by a site-specific mAb. (A) Schematic representation of α~1S~ and the epitope recognized by mAb 1A (residues 737--744; [@bib30]). α~1S~(726-YFP-727) is shown as an arbitrary example. (B--F) Confocal fluorescence images of mAb 1A binding (top, red), α~1S~ fluorescent protein distribution (middle, green), and the overlay of the antibody binding and α~1S~ distribution (bottom) are shown for dysgenic myotubes expressing YFP-α~1S~ (B), α~1S~(726-CFP-YFP-727) (C), α~1S~(726-YFP-727) (D), α~1S~(760-YFP-761) (E), and α~1S~(785-YFP-786) (F). The images represent optical sections near the myotube surface. In deeper optical sections, the overlapping red and yellow puncta were largely absent from the core of the myotube and were present only at the periphery (not depicted). Alexa Fluor 568--conjugated anti--mouse IgG was used to visualize the binding of mAb 1A. Bars, 5 µm.](JGP_200910241_RGB_Fig8){#fig8}

DISCUSSION
==========

In this study, we have evaluated the effects of fluorescent protein insertion as a tool for obtaining information about domains of the α~1S~ II--III loop (residues 662--799) that are essential for bidirectional coupling with RYR1. The insertions were at four sites: (1) replacing residues 672--685 within the peptide A region, (2) between residues 726 and 727 near the N-terminal boundary of the critical domain (residues 720--765), (3) between residues 760 and 761 near the C-terminal boundary of the critical domain, and (4) between residues 785 and 786 in the conserved C-terminal region of the α~1S~ II--III loop. Bidirectional coupling between DHPR and RYR1 displayed a differential sensitivity to insertions at these four sites. This coupling was unaffected by insertion of a large (∼56 kD) CFP--YFP tandem in place of the peptide A region but was ablated by the same insertion between α~1S~ residues 726 and 727. Bidirectional coupling was partially spared by insertion of only a single fluorescent protein (YFP) between α~1S~ residues 726 and 727 but totally eliminated by insertion either between α~1S~ residues 760 and 761 or between residues 785 and 786.

Each of the α~1S~ tandem constructs in which the CFP--YFP tandem was substituted for α~1S~ residues 672--685 ([Fig. 1, A--D](#fig1){ref-type="fig"}) functioned normally both as a voltage-gated Ca^2+^ channel and as a voltage sensor for EC coupling ([Figs. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}) regardless of whether the α~1S~ construct was expressed as a combination of two hemidomains (α~1S~ repeats I--II and repeats III--IV) or as an intact channel. This finding is in agreement with several previous studies demonstrating that EC coupling is unaffected by scrambling, deleting, or substituting unrelated sequence for the peptide A region of the α~1S~ II--III loop ([@bib44]; [@bib2],[@bib3]; [@bib67]; [@bib21]; [@bib35]; [@bib42]; [@bib34]). Clearly, these previous results had already indicated that the binding of the peptide A region to other junctional proteins is unnecessary for coupling with RYR1. It now seems possible to broaden this conclusion. First, the ability of the peptide A region to accommodate the CFP--YFP tandem, together with this region's accessibility to a large (∼60 kD) streptavidin probe ([@bib35]; [@bib34]), suggests that the segments of the α~1S~ II--III loop adjacent to the peptide A region are also fully exposed to the myoplasm at the triad junction and thus devoid of junctional interaction partners in both resting and depolarized cells. Second, it seems extremely unlikely that peptide A and/or immediately adjacent regions of the α~1S~ II--III loop are important for propagating signaling-related conformational changes to RYR1 because one might expect such conformational changes to be impeded by the presence of the CFP--YFP tandem.

Unlike insertions in the peptide A region, insertions of fluorescent protein in either the N- or C-terminal portions of the critical domain of the α~1S~ II--III loop significantly impacted bidirectional signaling. To evaluate these effects, it is useful to consider the landmarks of the critical domain. This region was initially characterized as α~1S~ residues 720--765 on the basis of functional analysis of chimeras between α~1S~ and α~1C~ ([@bib38]). The top portion of [Fig. 9](#fig9){ref-type="fig"} compares the sequence of these 46 α~1S~ residues (720--765) with the corresponding residues of α~1C~ (851--896) and α~1M~ (712--756). Subsequent work identified a slightly smaller region of 31 α~1S~ residues that was sufficient to restore full bidirectional signaling when inserted into a II--III loop otherwise having an α~1M~ sequence (chimera SkLMS~31~; [@bib31]). [Fig. 9](#fig9){ref-type="fig"} illustrates the position of this slightly smaller segment of the critical domain and also compares the sequences of α~1S~, α~1C~, and α~1M~ that extend from the C-terminal edge of the critical domain to the beginning of repeat IIIS1.

![Sequence comparison of the critical domain and C-terminal region of the α~1S~ II--III loop with the corresponding regions of α~1C~ and α~1M~. Sequence alignment is shown for rabbit α~1S~ (GenBank/EMBL/DDBJ accession no. [X05921](X05921)), rabbit α~1C~ (GenBank/EMBL/DDBJ accession no. [X15539](X15539)), and *M. domestica* α~1M~ (GenBank/EMBL/DDBJ accession no. [Z31723](Z31723)). The top panel (α~1S~ residues 720--765) represents the critical domain as defined by [@bib38]. The bottom panel (α~1S~ residues 766--799) represents the region of the II--III loop C-terminal to the critical domain, ending just before repeat III ([@bib62]). Sequence is not shown for the relatively divergent N-terminal portion of the II--III loop (α~1S~ residues 662--719). Residues of α~1C~ or α~1M~ identical to those of α~1S~ are shaded in black, and residues conserved with those of α~1S~ are shaded in gray. For the SkLMS~31~ chimera ([@bib31]), the black line indicates α~1S~ sequence inserted into the *M. domestica* loop. The epitope for binding of mAb 1A ([@bib30]) is boxed in orange. The conserved α~1S~/α~1C~ negative charge cluster is boxed in blue. Individual point mutation of any of the nonconserved α~1S~ residues indicated in red to the corresponding α~1C~ residues results in a decreased magnitude of skeletal-type EC coupling ([@bib31]) and loss of mAb 1A binding ([@bib30]). Black arrows indicate the positions of fluorescent protein insertion for α~1S~(726-CFP-YFP-727), α~1S~(726-YFP-727), α~1S~(760-YFP-761), or α~1S~(785-YFP-786) ([Fig. 1](#fig1){ref-type="fig"}).](JGP_200910241_RGB_Fig9){#fig9}

Insertion of the tandem within the N-terminal portion of the critical domain abolished bidirectional signaling ([Fig. 5, A--C](#fig5){ref-type="fig"}). This loss of signaling did not appear to be a consequence of loss of membrane expression because charge movements for α~1S~(726-CFP-YFP-727) were not significantly different from those of α~1S~(671-CFP-YFP-686) ([Fig. 4, A and B](#fig4){ref-type="fig"}; and [Table I](#tbl1){ref-type="table"}). Additionally, junctional targeting, as indicated by fluorescent puncta near the surface, appeared to be normal for α~1S~(726-CFP-YFP-727) ([Fig. 8 C](#fig8){ref-type="fig"}). Thus, it appears that tandem insertion between residues 726 and 727 specifically eliminated interaction with RYR1 because Ca^2+^ transients were absent and the currents for α~1S~(726-CFP-YFP-727) had amplitude and kinetics like those of Ca^2+^ current in dyspedic myotubes, where RYR1 is genetically absent ([@bib36], [@bib37]; [@bib5]; [@bib55]). One possibility for why bidirectional coupling is absent for α~1S~(726-CFP-YFP-727) is that the insertion of the tandem between residues 726 and 727 severed a sequence of the loop that binds to other junctional proteins. However, substantial alteration of the primary sequence surrounding α~1S~ residues 726 and 727, as occurs in the chimera SkLMS~31~ ([Fig. 9](#fig9){ref-type="fig"}), appears to have no effect on bidirectional signaling ([@bib31]). Another argument against the idea that interruption of the primary sequence accounts for the complete loss of coupling by α~1S~(726-CFP-YFP-727) is that coupling was partially preserved in the construct α~1S~(726-YFP-727), as shown in [Fig. 5 (D--F)](#fig5){ref-type="fig"}.

Compared with the N-terminal edge of the critical domain, the C-terminal edge appeared more sensitive to introduction of a single fluorescent protein. Thus, weak bidirectional signaling was present for the construct α~1S~(726-YFP-727) but was completely absent for the construct α~1S~(760-YFP-761). It should be noted that the YFP connecting linkers were substantially shorter for the insertion between residues 760/761 than for the insertion between residues 726/727 (see Materials and methods). Although the different linker length could have contributed to the greater effect of YFP insertion at residues 760/761 than at residues 726/727, it seems unlikely to account for the much greater effect of YFP insertion at residues 785/786 compared with residues 726/727 because the linker lengths were nearly identical at the two positions. Thus, it seems reasonable to conclude that bidirectional signaling is much more sensitive to perturbation at residues 785/786 than at residues 726/727.

The suppression of bidirectional signaling produced by inserting fluorescent proteins within the N- or C-terminal portions of the critical domain could, in principle, result from disruption of the tertiary structure of this entire region. However, the structure of this region did not appear to be severely altered because mAb 1A was able to recognize its epitope (α~1S~ residues 737--744) within the critical domain of the constructs α~1S~(726-CFP-YFP-727), α~1S~(726-YFP-727), α~1S~(760-YFP-761), and α~1S~(785-YFP-786) ([Fig. 8, C--F](#fig8){ref-type="fig"}).

The absence of bidirectional signaling for α~1S~(726-CFP-YFP-727) and α~1S~(760-YFP-761) is consistent with the idea that the binding of α~1S~ residues (727--760) to other junctional proteins (e.g., RYR1) is necessary for functional coupling. For example, one could hypothesize that voltage sensor movement in response to depolarization promotes a conformation of the α~1S~ II--III loop that favors the bound state of this region of the critical domain and, thus, both SR Ca^2+^ release and retrograde signaling. If this model were correct, the addition of the extra mass of fluorescent protein near either the N- or C-terminal boundaries of the critical domain could slow the on-rate for binding, shift the equilibrium toward the unbound state, and thus reduce the magnitude of bidirectional coupling. This kinetic model would explain why the CFP--YFP tandem with its greater mass had a larger effect when inserted after residue 726 than did YFP alone. A second hypothesis (occlusion model) is that the presence of the fluorescent proteins sterically occludes entry of α~1S~ II--III loop residues into a binding pocket. According to this model, the binding of residues 727--760 would be completely occluded by the presence of the CFP--YFP tandem between residues 726--727 but only partially occluded by a single YFP at this position.

Either the kinetic or occlusion model could be made compatible with the observation that bidirectional coupling was totally absent for α~1S~(760-YFP-761). With the kinetic model, for example, it could be postulated that the C-terminal segment of the α~1S~ II--III loop (roughly from residue 760 to repeat III) is essential for coupling between voltage sensor movement and the active conformation of the critical domain and that this coupling is drastically slowed by the presence of fluorescent protein between α~1S~ residues 760 and 761. Alternatively, the YFP placed between α~1S~ residues 760 and 761 might directly interfere with the binding of the adjacent critical domain residues to other junctional proteins.

Whether or not these aforementioned specific hypotheses have validity, it is important to recognize that the region of the α~1S~ II--III loop downstream from the critical domain is well conserved between α~1S~, α~1C~, and α~1M~ ([Fig. 9](#fig9){ref-type="fig"}, bottom), which means that its importance has not been previously tested by chimeras between these channels. In this regard, the ablation of both orthograde and retrograde coupling by introduction of YFP between α~1S~ residues 785 and 786 ([Fig. 7](#fig7){ref-type="fig"}) clearly indicates that the integrity of this region is vital for skeletal-type EC coupling. It remains to be determined whether this domain functions as a conduit for intramolecular communication between the voltage sensor and the critical domain or whether it serves as a site for intermolecular interactions that support bidirectional communication between DHPR and RYR1.

In addition to functional evidence for the importance of the critical domain of the α~1S~ II--III loop, yeast two-hybrid assays have revealed a weak interaction between the critical domain and a segment of RYR1 (residues 1,837--2,168; [@bib45]). Freeze-fracture electron microscopy also provides structural evidence that the critical domain of the α~1S~ II--III loop is important for linking DHPRs to RYR1. In particular, the arrangement of DHPRs into tetrads depends on the presence of RYR1 in the SR at sites of junction with the plasma membrane ([@bib46], [@bib48], [@bib47]). Tetrads are not formed upon expression in dysgenic myotubes of a chimera consisting of α~1S~ with a II--III loop having an α~1C~ sequence (SkLC), but tetrads are formed when the critical domain portion of the loop of SkLC is converted back to an α~1S~ sequence ([@bib59]). Interestingly, however, relatively good tetrad formation was observed for a chimera (SkLM) consisting of α~1S~ with a II--III loop having an α~1M~ sequence ([@bib59]), even though this construct did not support skeletal-type EC coupling ([@bib67]).

[@bib3] found that a one-piece α~1S~ construct lacking the critical domain did not mediate skeletal-type EC coupling, but a construct lacking both the critical domain and the peptide A region did support weak coupling, producing maximal transients of ∼15% of the amplitude of wild-type α~1S~. Thus, in addition to the critical domain, other regions of the DHPR have some ability to participate in the interactions that support EC coupling. The organization of SkLM into tetrads ([@bib59]) also implies that yet-to-be-identified regions of the DHPR must participate in the interactions linking the DHPR to RYR1. Our present results ([Figs. 2--7](#fig2){ref-type="fig"}[](#fig3){ref-type="fig"}[](#fig4){ref-type="fig"}[](#fig5){ref-type="fig"}[](#fig6){ref-type="fig"}[](#fig7){ref-type="fig"}) raise the possibility that one of these yet-to-be-identified regions is the portion of the α~1S~ II--III loop that is C-terminal to the critical domain ([Fig. 9](#fig9){ref-type="fig"}, bottom).

In addition to the critical domain and C-terminal region of the α~1S~ II--III loop, other DHPR domains are also possible sites involved in coupling to RYR1. For example, the C-terminal region of β~1a~ strongly influences bidirectional signaling ([@bib13]; [@bib52],[@bib53], [@bib54]; [@bib27]). β~1a~ also facilitates tetrad formation, as the β~1a~-null zebrafish mutant relaxed lacks the characteristic orthogonal DHPR arrays typically observed in freeze-fracture replicas of normal skeletal muscle ([@bib50], [@bib49]). Other possible sites that may interact with RYR1 are the α~1S~ III--IV loop ([@bib33]; but see [@bib10]) and proximal portions of the C terminus of α~1S~ ([@bib56]; [@bib20]; [@bib43]; [@bib51]; [@bib35]; [@bib42]; [@bib34]).

Overall, the effects of inserting fluorescent proteins into the α~1S~ II--III loop are consistent with the idea that binding of the α~1S~ II--III loop critical domain to other junctional proteins is important for bidirectional signaling. Our current results expand our knowledge of the mechanism of bidirectional coupling by identifying the importance of the conserved region of the α~1S~ II--III loop that connects the critical domain to α~1S~ repeat III. However, our results do not exclude roles for other regions of the DHPR that have been implicated as involved in coupling with RYR1. Indeed, it seems quite likely that several cytoplasmic regions of the DHPR, in addition to those already implicated, participate in interactions that positively or negatively influence coupling between the DHPR and RYR1 ([@bib7]). However, we are now in a position to exclude at least a couple of regions from likely involvement. One such region is the N terminus of α~1S~, which can be largely deleted without affecting function ([@bib8]). Based on both previous results ([@bib44]; [@bib2],[@bib3]; [@bib21]; [@bib35]; [@bib42]; [@bib34]) and those described in this study, it also seems possible to exclude the involvement of peptide A and adjacent regions of the N-terminal portion of the α~1S~ II--III loop as an essential trigger for EC coupling.

The fact that gating of RYR1 is responsive to voltage across the plasma membrane means that the functional state of the DHPR must control the conformation of at least some of the cytoplasmic DHPR regions important for coupling. Regions of this sort may be difficult to define by standard biochemical or structural approaches. Thus, it is likely to continue to be of value to use the kinds of approaches described here to probe the importance of other cytoplasmic domains of the DHPR.
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